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Abstract Multiple endocrine neoplasia type 1 (MEN 1) is 
inherited as an autosomal dominant disorder, characterized 
by hyperplasia and neoplasia in several endocrine organs. 
The MEN 1 gene, which is most probably a tumor sup­
pressor gene, has been localized to a 900-kb region on 
chromosome 11 q 13. The human phosphatidylinositol-spe­
cific phospholipase C (33 (PLC (33) gene, which is located 
within this region, was considered to be a good candidate 
for the MEN 1 gene. In this study, the structure and ex­
pression of the PLC (33 gene in MEN 1 patients were in­
vestigated in more detail, to determine its potential role in 
MEN 1 tumorigenesis. Southern blot analysis, using blood 
and tumor DNA from affected persons from seven differ­
ent MEN 1 families, did not reveal structural abnormali­
ties in the PLC (33 gene. To detect possible point muta­
tions, or other small structural aberrations, direct sequenc­
ing of PLC (33 cDNAs from two affected persons from two 
different MEN 1 families was performed, but no MEN 1 - 
specific abnormalities were revealed. Several common 
nucleotide sequence polymorphisms were detected in these 
cDNAs, proving that both alleles of the PLC (33 gene 
were expressed and analyzed. In conclusion, these results 
exclude the PLC (33 gene as a candidate gene for MEN 1.
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Multiple endocrine neoplasia type 1 (MEN 1) is a heredi­
tary cancer syndrome with an autosomal dominant pattern 
of inheritance. The disorder is characterized by the com­
bined occurrence of hyperplasia or tumors of the parathy­
roid glands, the pancreatic islets and the anterior pituitary 
gland (Larsson and Nordenskjold 1990), Using linkage 
analysis in MEN 1 families and allelotyping of MEN 1- 
associated tumors, the hereditary genetic defect has been 
assigned to chromosome 11 q 13 (Larsson et al. 1988). 
Elimination of the wild-type allele at 11 qL3 loci in MEN 
1 tumors suggests inactivation of a tumor suppressor gene 
in this region as the causative mechanism in MEN 1 tu­
morigenesis (Larsson et al. 1988).
Loss of heterozygosity studies revealed a smallest region 
of overlapping deletions in MEN 1-associated tumors, 
flanked by the loci DI1S427 and D11S97 (Weber et al. 
1994). Previous linkage analysis showed meiotic recom­
binants in MEN 1 families for locus D11S807 (Larsson et 
al. 1992). These studies place the MEN 1 locus between 
D11S427 on the centromeric side and D11S807 on the 
telomeric side, a region of at most 900 kb (Weber et al.
1994).
Recently, the phosphatidylinositol-specific phospholi­
pase C (33 (PLC (33) gene has been localized to this 900- 
kb region (Weber et al. 1994; Sinke and Geurts van Kessel
1995). Phosphatidylinositol-specific phospholipases C are 
involved in cell surface receptor-mediated signal trans­
duction pathways. PLC ¡3 enzymes have been shown to 
interact with heterotrimeric GTP-binding proteins (G pro­
teins), which are linked to seven transmembrane receptors 
(Meldrum et al. 1991), such as the receptors for many 
polypeptide hormones.
Because of its chromosomal location and the role of its 
encoded protein in signal transduction, the PLC (33 gene 
seemed a very good candidate for the MEN 1 gene. An 
additional indication for its involvement in MEN 1 tumori­
genesis was provided by reduced or undetectable expres­
sion of PLC p3 in several sporadic and familial MEN 1-
related tumors (Weberel al. 1994). This finding was what 
one would expect for the MEN 1 tumor suppressor gene, 
since inactivation or loss of the wild-type allele could re­
sult in lower expression levels of the predisposing gene in 
MEN I tumors.
In the present study, the structure and expression of the 
PLC [33 gene were examined in MEN I patients, in order 
to screen for MEN I-specific abnormalities. Southern blot 
analysis of constitutional DNA from affected persons from 
seven different MEN 1 families, as well as DNA from 
three MEN 1-related tumors, was performed, to screen tor 
large aberrations in the FLC (33 gene. In addition, we 
screened for small aberrations, by sequencing the entire 
coding region of FLC [33 cDNA, derived from fibroblast 
and tumor RNA from affected persons from two different 
MEN 1 families. In cases where a nucleotide sequence vari­
ant was detected, we sequenced the DNAs of other affected
and nonaffected persons from the same MEN 1 families to 
determine whether such variants represent MEN 1-specific 
mutations, or common nucleotide sequence polymorphisms.
Materials and methods
Materia is
Blood was obtained from MEN 1 patients and nonaffected persons 
from seven unrelated families. MEN I tum or tissue was obtained 
from two Hlucaaonomas and one insulinoma from three individual 
patients. From one patient a fibroblast celt culture was used for 
isolation of total cellular RNA.
DNA isolation and Southern blot analysis
DNA was isolated from blood and tumor samples using a high-salt 
method (Miller et al. 1988). £twRI-, Tacjl-, and jSamHI-digested
Table 1 Nucleotide sequences 
o f phosphoiipase C (PLC) (33~ 
specific oligonucleotides used 
in polymerase chain reaction 
(PCR) and sequencing reac­
tions. Forward primers are in- 
dieated by (F),  reverse primers 
by (R ). The numbering of posi­
tion in the cDNA is aecordiniz 
to that published by Sinke and 
Geurts van Kessel (1994). This 
numbering was also applied for 
the part of the sequence pub­
lished by Carozzi et al. (1992)
Primers used in PCR and sequencing reactions
Primer Nucleotide sequence Position in cD N A
PLC 1 (R) 5/-G G A G G A TG A A G G G A G TTA G C-3/ 3863/3844
PLC 2 (F) 5 '-CTG G A A CA CCTG A G A CA G G C-3' 3171/3190
PLC 3 (R) 5 '-CA TCTTG G CCTCCG A G A TG C-3' 3332/3313
PLC 4 (F) 5 '-TTTG G CCTCCCTG TTG A TA CG C-3' 2253/2274
PLC 5 (R) 5 '-G G A G G CA TCCA G TG G G CTG G -3' 2747/2728
PLC 6 (F) 5 '-A A G TCCTTTG A G G CTG CTCG -3' 1806/1825
PLC 7 (R) 5 '-G CTG CA TCG CCA CA TCG A G G -3' 2052/2033
PLC 8 (F) 5#-A A G A A G CG G CA CCG A CCCA G CG C-3' 1401/1423
PLC 9 (R) 5'-AGC AGGTCCA AGAACAT AGG-3' 1658/1639
PLC 10(F) 5 '-CA A G A TCCTG CTG G A G A TA G G C-3' 680/ 701
PLC Î 1 (R) 5 '-A G CA CG TCG CG CA G AG G CA C-3' 1177/1158
PLC 12 (F) 5 '-G G CCTCA A A TTCA A CCG G A G -3' 579/ 598
PLC 13 (R) 5 '-CTTCG TTG AG TCTCGG G TCG -3' 783/ 764
PLC 14 (F) 5 '-TCG G TCCCCG TCA GG G CTC-3' - 5 0 /  -3 2
PLC 24 (F) 5'-ATGGCCGTGCAGGATGACAC~3' 360/ 379
PLC 25 (R) 5 '-CAG G A TG TTCA TA G CCA G C-3' 428/ 410
PLC 26 (F) 5 '-G A G TCA G TCA A CTCCA TCCG -3' 3390/3409
PLC 27 (R) 5/-CTGCTCCTGA CACTCCTGG -3/ 3536/3518
PLC 29 (R) 5 /-CG TG TCCTCCACA TCA GCG -3/ 3061/3043
PLC 30 (F) 5 '-CA A G A G CG A G A CCTG CG G -3' 2907/2924
Primers used in sequencing reactions only
Primer Nucleotide sequence Position in cD N A
PLC 19 (F) 5 '-TG G G A G G CG A G G A G A A TG G -3' 898/ 916
PLC 20 (F) 5 '-CTG G A CG TG TG G A A G G G A CG -3' 1086/1105
PLC 21 (F) 5 '-A G CA A TG G G G A G G A G G T A G G -3' 1557/1576
PLC 22 (R) 5 '-G CG A A G TG A A G CCA G CG TG G -3' 2384/2363
PLC 23 (F) 5 '-A G CTG G CCG CCCTCA TTG G -3' 2623/2641
PLC 28 (R) 5 '-G G CTCTTG GTCA G TTG CTCC-3' 1897/1878
PLC 31 (R) 5 '-T  AGTGTC A TTG CCTCCTG CC-3' 3772/3753
Intron primers used to amplify PLC (33 exon 13 (according to intron sequences provided by Lager- 
c ra n tz e ta l .  1995)
Primer
PLC i 15 (F) 
PLC i 16 (R)
Nucleotide sequence
5'-TG A CTCG TCCA TG CCTG C-3' 
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subsequent nucleotide sequence analysis, and since both 
alleles of the PLC p3 gene were expressed, no indications 
for mutations at exon-intron junctions or in the promoter 
region were obtained. In conclusion, these results make it 
highly unlikely that the PLC (33 gene is the MEN 1 gene.
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